Skip to main content
Topas Therapeutics GmbH

Falkenried 88, Haus A
20251 Hamburg GERMANY

+49 40 302089010

Author: Topas Therapeutics

Anne Burger

Anne serves as Financial Advisor at Topas. She brings more than 15 years of experience in financial operations at biotech and medtech companies throughout Europe. She previously served as the CFO and Co-Founder of Breath Therapeutics GmbH, where she was instrumental in securing the financing (EUR 43.5 million) as well as executing the sale of the company to Zambon S.p.A. in 2019, with a deal value up to EUR 500 million. Anne also served as CFO at Rigontec and had an active role in the execution of Rigontec’s trade sale to MSD (known as Merck & Co. in North America), a deal worth up to EUR 464 million. Throughout her career, Anne has been responsible for corporate fundraising, executing trade sales and licensing agreements, and preparing for IPOs in several senior executive and advisory roles in the life sciences industry. Anne holds a graduate degree in Business Administration from Ludwig-Maximilians-University in Munich and has completed graduate studies in public health.

Cristina de Min, MD

Cristina joined Topas in September 2021 and is responsible for all clinical development programs. She spent 11 years at Roche in various executive positions, including Life Cycle Leader for the development of the IL-6 receptor antagonist tocilizumab (Actemra) for rheumatic diseases. She also served as Medical Director of Roche’s affiliate in Italy. Following Roche, she joined Novimmune, serving for nine years as Chief Medical Officer before the company was acquired by Swedish Orphan Biovitrum (SOBI). At Novimmune, she set up the clinical development department and was responsible for the global development strategy for drug candidates from translational activities through clinical development and registration. Cristina received her MD and board certification in endocrinology from the University of Milan.

Mireia Gomez-Angelats, PhD

Mireia joined Topas Therapeutics in October 2022 and is responsible for driving the company’s growth and business development as well as coordinating communications and other strategic corporate activities. She brings over 20 years of international pharmaceutical experience with roles of increasing responsibility in R&D and business development/licensing (BD&L). Prior to joining Topas, Mireia held global senior management positions at leading pharmaceutical companies, including Novartis AG in Switzerland and at Bristol Myers-Squibb in the US. She also held roles in R&D at Janssen (Johnson & Johnson) in the US and at Almirall SA in Barcelona (Spain). In her various positions, she has contributed to the expansion of strategic areas both by driving discovery and development programs and through the execution of a number of strategic deals and partnering activities across immunology, oncology, and cardiometabolic disease areas. Mireia holds a PhD in biochemistry and molecular biology from the University of Barcelona, Spain.

Christian Schröter, PhD

Christian joined Topas Therapeutics in June 2022 and is responsible for all CMC (chemistry, manufacturing & controls) activities, as well as project management. He spent 22 years at Merck in pharmaceutical R&D and operations, most recently as Head of Strategy, Global Healthcare Operations. His experience covers the healthcare value chain from late-stage research, pharmaceutical development and sterile production to franchise support and operations strategy. Christian is trained as a biochemist and received his PhD in immunology from Eberhard-Karls-University in Tübingen, Germany.